1. A histone deacetylase-reaction product, O-acetyl-ADP ribose.
2. A pharmaceutical composition comprising the reaction product of claim 1 in a biologically acceptable carrier medium.
3. An isolated antibody immunologically specific for O-acetyl ADP ribose.
4. The isolated antibody of claim 3, wherein said antibody is monoclonal.
5. The isolated antibody of claim 3, wherein said antibody is polyclonal.
6. A method for isolating test compounds having binding affinity for O-acetyl ADP ribose comprising:
a) providing immobilized O-acetyl ADP ribose;
b) contacting said immobilized O-acetyl ADP ribose with a test compound suspected of having binding affinity for said O-acetyl ADP ribose; and
c) eluting said immobilized O-acetyl ADP ribose and assessing eluate for the presence of said test compound.
7. The method as claimed in claim 6, wherein said test compound is a protein present in a cell extract.
8. The method as claimed in claim 6, wherein said O-acetyl ADP ribose is immobilized on a column.
9. The method as claimed in claim 6, wherein said O-acetyl ADP ribose is immobilized on a multiwell plate.
10. A method for producing O-acetyl ADP ribose in a cell, comprising:
a) transforming a host cell with a gene selected from group consisting of HST2, SIR2, HST1, HST3, HST4, CobB and homologues thereof;
b) isolating a protein encoded by said gene from said transformed host cell;
c) contacting said isolated protein with detectably labeled AcLYs-14 H3 peptide and NAD+ under conditions suitable for deacetylation to occur; and
d) isolating said O-acetyl ADP ribose.
11. A method as claimed in claim 10, wherein said detectable label is selected from the group consisting of fluorescein, rhodamine, radioactive isotopes, and chemiluminescence labels.
12. O-acetyl-ADP ribose as claimed in claim 1, wherein said O-acetyl-ADP ribose is detectably labeled.
13. O-acetyl-ADP ribose as claimed in claim 12, wherein said detectable label is selected from the group consisting of fluorescein, rhodamine, radioactive isotopes, and chemiluminescence labels.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A yarn comprising copolymer derived from the copolymerization of para-phenylenediamine, 5(6)-amino-2-(p-aminophenyl)benzimidazole, and terephthaloyl dichloride, wherein the ratio of moles of 5(6)-amino-2-(p-aminophenyl)benzimidazole to the moles of para-phenylenediamine is 3070 to 8515;
said yarn having a sulfur content greater than 0.1%; and
the hydrolytic strength retention of the yarn is greater than 60%;
wherein the hydrolytic strength retention is computed by dividing the strength of a skein of yarn treated with saturated steam at 150\xb0 C. for 24 hours by the strength of an untreated skein of yarn and multiplying by 100.
2. The yarn of claim 1, wherein the ratio of moles of 5(6)-amino-2-(p-aminophenyl)benzimidazole to the moles of para-phenylenediamine is 4555 to 8515.
3. The yarn of claim 1, wherein the hydrolytic strength retention of the yarn is greater than 70%.
4. The yarn of claim 1, wherein the hydrolytic strength retention of the yarn is greater than 80%.
5. The yarn of claim 1, wherein at least 20% of the imidazole nitrogens are in a free base state.
6. A process for preparing a yarn derived from the copolymerization of para-phenylenediamine, 5(6)-amino-2-(p-aminophenyl)benzimidazole, and terephthaloyl dichloride wherein the ratio of moles of 5(6)-amino-2-(p-aminophenyl)benzimidazole to the moles of para-phenylenediamine is 3070 to 8515; said yarn having a sulfur content greater than 0.1%, said process comprising:
a) forming said yarn by spinning and collecting said yarn from an inorganic acid solvent; and
b) washing said yarn with a basic aqueous solution for at least 5 seconds; wherein the hydrolytic strength retention of the yarn is greater than 60%;
wherein the hydrolytic strength retention is computed by dividing the strength of a skein of yarn treated with saturated steam at 150\xb0 C. for 24 hours by the strength of an untreated skein of yarn and multiplying by 100.
7. The process of claim 6, wherein the ratio of moles of 5(6)-amino-2-(p-aminophenyl)benzimidazole to the moles of para-phenylenediamine is 4555 to 8515.
8. The process of claim 6, wherein the hydrolytic strength retention of the yarn is greater than 70%.
9. The process of claim 6, additionally comprising:
c) heating said yarn to a temperature of at least 380\xb0 C.
10. The process of claim 6, wherein at least 20% of the imidazole rings are in a free base state.
11. A process for making a yarn from filaments comprising a copolymer derived from the copolymerization of para-phenylenediamine, 5(6)-amino-2-(p-aminophenyl)benzimidazole, and terephthaloyl dichloride having a sulfur content greater than 0.1% comprising the steps of:
a) spinning and collecting an acid-laden yarn; and
b) in a separate step, first washing the acid-laden yarn with a basic solution to form a neutralized yarn, followed by heat treating the yarn;
wherein the hydrolytic strength retention of the yarn is greater than 60%;
wherein the hydrolytic strength retention is computed by dividing the strength of a skein of yarn treated with saturated steam at 150\xb0 C. for 24 hours by the strength of an untreated skein of yarn and multiplying by 100.
12. The process of claim 11, wherein the yarn in step b) is washed with the basic aqueous solution and water for a total time duration of greater than 5 seconds.
13. The process of claim 11, additionally comprising:
c) heating said yarn to a temperature of at least 380\xb0 C.
14. The process of claim 11, wherein the yarn in step b) is first washed with aqueous media prior to washing with a sodium hydroxide solution.
15. The process of claim 11, wherein the washing(s) and heat treating is a continuous process.